Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034879 · ClinicalTrials.gov registry record · Phase 3
Iressa Expanded Access Program (EAP)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00034879: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00034879 is a Phase 3 study that has completed, run by AstraZeneca. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034879, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.
Interventions
- DRUG ZD1839 (Gefitinib)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Est. Completion | 2003-10 |
| Phase | Phase 3 |
What the finished NCT00034879 record still lists
NCT00034879 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ZD1839 (Gefitinib) is the first listed.
NCT00034879 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00034879 about?
NCT00034879 is a clinical study titled "Iressa Expanded Access Program (EAP)". A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.
What is the current status of trial NCT00034879?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-08. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00034879?
The interventions under investigation include: ZD1839 (Gefitinib) (DRUG).
Who is sponsoring clinical trial NCT00034879?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia